Next week HCS Pharma will be present at SFBMEc Reims (15th-17th May).

We will present a poster about the influence of BIOMIMESYS® hydroscaffold composition and stiffness on the 3D culture of breast cancer cells. The poster will be avalaible next week, but if you want it before, you can contact us.

The extracellular matrix (ECM) is present in all solid tissues and is a master regulator of cell behavior and phenotype. The ECM in each tissue is characterized by its biochemical and biophysical properties, which are modified in many different types of disease, especially cancer. Hyaluronic acid (HA), as a biopolymer, has emerged as a remarkable ECM component by its viscoelastic properties, its hygroscopic capacities and the diversity of cell processes it controls in health and disease.
BIOMIMESYS®, a patented HA-based hydroscaffold, is a highly reproducible and physiological matrix that is suitable for long-term 3D cell culture. Using BIOMIMESYS® Oncology – made of HA biofunctionalized with undenaturated collagen I – we investigated the influence of (i) matrix composition (with/without laminin) and (ii) stiffness on the growth and expression of CD44 (a receptor of HA) in spheroids made of breast cancer cell lines (MCF7, MDA-MB-231) and normal cells (MCF10A) along time. Analyses were carried out using high content analysis/screening (HCA/HCS, high throughput confocal microscopy).

Partial abstract of the poster “Impact of the composition and stiffness of a 3D hyaluronic acid-based hydroscaffold on breast cancer cell growth and CD44 expression”

For all information about our technology and our researches, please feel free to meet our scientists Elodie et Zied (send us a email)

Looking forward to meeting you there!


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.